SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201500073C-3-0-0
Agency Tracking Number: N43CA150073
Amount: $1,999,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2017
Award Year: 2015
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
115A Commerce Drive, BROOKFIELD, CT, 68043
DUNS: 966566465
HUBZone Owned: Unavailable
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOSEPH BACKER
 (203) 775-5677
 joseph.backer@gmail.com
Business Contact
 JOSEPH BACKER
Phone: (203) 775-5677
Email: joseph.backer@gmail.com
Research Institution
N/A
Abstract
The overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vasculature in some patients but cause only marginal if any improvement in overall survival in many cancer patients Our data in mouse models of primary and metastatic breast cancer indicate that scV Lu induces a sustainable vascular regression inhibits growth of primary tumor and metastatic lesions improves overall survival and readily combines with front line chemotherapy scV is a proprietary recombinant single chain vascular endothelial growth factor scVEGF engineered for site specific derivatization with PEGylated chelators which binds to and internalized by VEGF receptors with native affinity In Phase I of this contract using syngeneic mouse model of orthotopic breast cancer we will establish if selective targeting of VEGFR or VEGFR with scV Lu may provide additional therapeutic benefits and define our lead candidate for further development In Phase II we will develop the lead scV Lu candidate through late preclinical development GMP production dosimetry toxicology and undertake physician initiated exploratory Phase I trial in cancer patients

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government